Version July 2025
Tinea corporis (ringworm): Children ≥2 years and Adolescents: Cream 2%: Topical: Apply to affected and surrounding area(s) once daily until clinical resolution; typically 2 weeks.
Tinea cruris (jock itch): Children ≥12 years and Adolescents: Cream 2%: Topical: Apply to affected and surrounding area(s) once daily until clinical resolution; typically 2 weeks.
Tinea pedis (athlete's foot): Children ≥12 years and Adolescents: Topical: Gel 2%, Cream 2%: Topical: Apply to affected and surrounding area(s) once daily until clinical resolution; typically 2 to 4 weeks (Ref).
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
(For additional information see "Naftifine: Drug information")
Tinea infection:
Tinea corporis/tinea cruris: Topical:
Cream 1% and 2%, gel 1%: Apply to affected and surrounding area(s) once daily (cream) or twice daily (gel) until clinical resolution, typically 1 to 4 weeks; resolution may be faster with 2% cream (Ref).
Tinea pedis (labeled use)/tinea manuum (off-label use): Topical:
Cream 1% and 2%, gel 1% and 2%: Apply to affected and surrounding area(s) once daily (cream and 2% gel) or twice daily (1% gel) until 1 week after clinical resolution, typically for 2 to 4 weeks total; resolution may be faster with 2% formulations (Ref).
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
1% to 10%:
Dermatologic: Burning sensation of skin (5% to 6%), xeroderma (3%), skin irritation (2%), erythema (≤2%), pruritus (1% to 2%)
Local: Application site reaction (2%)
<1%, postmarketing, and/or case reports: Agranulocytosis, crusted skin, dizziness, headache, inflammation, leukopenia, maceration, pain, rash, serous drainage, skin blister, skin tenderness, swelling of skin
Hypersensitivity to naftifine or any component of the formulation
Concerns related to adverse effects:
• Irritation: Discontinue if sensitivity or irritation occurs and institute appropriate therapy.
Other warnings/precautions:
• Appropriate use: For topical use only; not intended for oral, ophthalmic, or vaginal use. Avoid use of occlusive dressings and contact with eyes, nose, mouth, or mucous membranes.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Cream, External, as hydrochloride:
Generic: 1% (60 g, 90 g); 2% (45 g, 60 g)
Gel, External, as hydrochloride:
Naftin: 1% (40 g [DSC], 60 g [DSC], 90 g [DSC]) [contains alcohol, usp, edetate (edta) disodium, polysorbate 80]
Naftin: 2% (45 g, 60 g) [contains alcohol, usp, benzyl alcohol, edetate (edta) disodium, propylene glycol, trolamine (triethanolamine)]
Generic: 1% (40 g [DSC], 60 g [DSC], 90 g [DSC]); 2% (45 g, 60 g)
Yes
Cream (Naftifine HCl External)
1% (per gram): $6.26
2% (per gram): $8.88
Gel (Naftifine HCl External)
2% (per gram): $11.30
Gel (Naftin External)
2% (per gram): $13.58
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Topical: Cream 2%, Gel 2%: For topical use only; avoid nasal, ophthalmic, oral, or intravaginal use. Wash hands before and after use. Apply to clean, dry skin. Apply to the affected area(s) and a 1/2-inch margin of healthy surrounding tissue. Avoid occlusive dressings.
Topical: For topical use only; avoid nasal, ophthalmic, oral or intravaginal use. Wash hands before and after use. Apply to clean, dry skin. Avoid occlusive dressings.
Cream 1%: Store below 30°C (86°F).
Cream 2%, gel 2%: Store at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).
Gel 1%: Store at room temperature.
Gel 2%: Topical treatment of interdigital tinea pedis (FDA approved in ages ≥12 years and adults).
Cream 2%: Topical treatment of tinea corporis (FDA approved in ages ≥2 years and adults); topical treatment of tinea cruris and interdigital tinea pedis (FDA approved in ages ≥12 years and adults).
Cream 1%: Topical treatment of tinea cruris, tinea corporis, and tinea pedis (FDA approved in adults).
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program
There are no known significant interactions.
Naftifine is absorbed systemically (4% to 6%) following topical administration. Application over a limited area is considered likely acceptable during pregnancy (Patel 2017).
Monitor application site for irritation or sensitivity.
Synthetic, broad-spectrum antifungal agent in the allylamine class; appears to have both fungistatic and fungicidal activity. Exhibits antifungal activity by selectively inhibiting the enzyme squalene epoxidase in a dose-dependent manner which results in a reduced synthesis of ergosterol, the primary sterol within the fungal membrane, and increased squalene in cells.
Absorption: Systemic: Cream: 6%; Gel: 4%
Half-life elimination: 2 to 3 days
Excretion: Urine and feces (as unchanged drug and/or metabolites)
